Advertisement

Phytothérapie

, Volume 9, Issue 1, pp 48–52 | Cite as

Le Hericium erinaceus: des propriétés essentiellement dépendantes du neuronal growth factor

  • B. Donatini
Formation Continue Mycothérapie

Résumé

Le Hericium erinaceus (HE) induit la synthèse de neuronal growth factor (NGF), impliqué dans les maladies neurodégénératives comme la maladie d’Alzheimer ou plus généralement dans les troubles trophiques (estomac, intestin, foie) ou les cicatrisations (peau, cartilage, os). Le HE stimule aussi les voies TH1 et TH2 (antiparasitaire puissant), ce qui le positionne parmi les aliments potentiellement utiles contre les maladies auto-immunes IL17-dépendantes. L’effet du NGF dépend de la vitamine D.

Mots clés

Champignon Neuronal growth factor 

Hericium erinaceus: properties mostly related to the secretion of neuronal growth factor

Abstract

Hericium erinaceus induces the synthesis of neuronal growth factor (NGF), implicated in neuro-degenerative diseases such as Alzheimer dementia or more generally in atrophic diseases (stomac, intestinal mucosa, liver) or fibroblasts, chondrocytes or osteoblasts stimulation. HE also stimulates immunity, especially TH1 and TH2 pathways which enables this mycelia to be considered as a good candidate in auto-immune diseases therapy. The efficacy of NGF relies on an adequate titration of vitamin D.

Keywords

Mushroom Neuronal growth factor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliographie

  1. 1.
    Aloe L, Bracci-Laudiero L, Bonini S, Manni L (1997) The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 52: 883–894PubMedCrossRefGoogle Scholar
  2. 2.
    Aloe L, Manni L, Properzi F, et al. (2000) Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci 86: 84–93PubMedCrossRefGoogle Scholar
  3. 3.
    Althaus HH (2004) Remyelination in multiple sclerosis: a new role for neurotrophins? Prog Brain Res 146: 415–432PubMedCrossRefGoogle Scholar
  4. 4.
    Arancibia S, Assenmacher I (1985) Submaxillary glands in an endocrine context (article in French). J Biol Buccale 13: 185–203PubMedGoogle Scholar
  5. 5.
    Arredondo LR, Deng C, Ratts RB, et al. (2001) Role of nerve growth factor in experimental autoimmune encephalomyelitis. Eur J Immunol 31: 625–633PubMedCrossRefGoogle Scholar
  6. 6.
    Asaumi K, Nakanishi T, Asahara H, et al. (2000) Expression of neurotrophins and their receptors (Trk) during fracture healing. Bone 26: 625–633PubMedCrossRefGoogle Scholar
  7. 7.
    Bayas A, Kruse N, Moriabadi NF, et al. (2003) Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells. Neurosci Lett 335: 155–158PubMedCrossRefGoogle Scholar
  8. 8.
    Bonini S, Lambiase A, Bonini S, et al. (1999) Nerve growth factor: an important molecule in allergic inflammation and tissue remodel-ling. Int Arch Allergy Immunol 118: 159–162PubMedCrossRefGoogle Scholar
  9. 9.
    Bonini S, Rasi G, Bracci-Laudiero ML, et al. (2003) Nerve growth factor: neurotrophin or cytokine? Int Arch Allergy Immunol 131: 80–84PubMedCrossRefGoogle Scholar
  10. 10.
    Braun S, Croizat B, Lagrange MC, et al. (1996) Neurotrophins increase motoneurons’ ability to innervate skeletal muscle fibers in rat spinal cord: human muscle cocultures J Neurol Sci 136: 17–23PubMedCrossRefGoogle Scholar
  11. 11.
    Brodie C (1996) Differential effects of TH1 and TH2 derived cytokines on NGF synthesis by mouse astrocytes. FEBS Lett 394: 117–120PubMedCrossRefGoogle Scholar
  12. 12.
    Brown J, Bianco JI, McGrath JJ, Eyles DW (2003) 1,25-dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 343: 139–143PubMedCrossRefGoogle Scholar
  13. 13.
    Cavaletti G, Bogliun G, Marzorati L, et al. (2004) Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 15: 1439–1442PubMedCrossRefGoogle Scholar
  14. 14.
    Chaldakov GN, Fiore M, Stankulov IS, et al. (2004) Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res 146: 279–289PubMedCrossRefGoogle Scholar
  15. 15.
    Chaldakov GN, Fiore M, Tonchev AB, et al. (2007) Homo obesus: a metabotrophin-deficient species. Pharmacology and nutrition insight. Curr Pharm Des 13(21): 2176–2179PubMedCrossRefGoogle Scholar
  16. 16.
    Choi WS, Kim CJ, Park BS, et al. (2005) Inhibitory effect on proliferation of vascular smooth muscle cells and protective effect on CCl(4)-induced hepatic damage of HEAI extract. J Ethnopharmacol 22: 176–179CrossRefGoogle Scholar
  17. 17.
    Cirulli F, Alleva E, Antonelli A, Aloe L (2000) NGF expression in the developing rat brain: effects of maternal separation. Brain Res Dev Brain Res 123: 129–134PubMedCrossRefGoogle Scholar
  18. 18.
    Cornet A, Baudet C, Neveu I, et al. (1998) 1,25-Dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. J Neurosci Res 53: 742–746PubMedCrossRefGoogle Scholar
  19. 19.
    Coulie B, Szarka LA, Camilleri M, et al. (2000) Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 119: 257–260CrossRefGoogle Scholar
  20. 20.
    Dissen GA, Garcia-Rudaz C, Paredes A, et al. (2009) Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinology 150: 2906–2914PubMedCrossRefGoogle Scholar
  21. 21.
    Dissen GA, Lara HE, Leyton V, et al. (2000) Intraovarian excess of nerve growth factor increases androgen secretion and disrupts estrous cyclicity in the rat. Endocrinology 141: 1073–1082PubMedCrossRefGoogle Scholar
  22. 22.
    Dong Q, Jia LM, Fang JN (2006) A beta-D-glucan isolated from the fruiting bodies of Hericium erinaceus and its aqueous conformation. Carbohydr Res 341: 791–795PubMedCrossRefGoogle Scholar
  23. 23.
    Dyck PJ, Peroutka S, Rask C, et al. (1997) Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 48: 501–505PubMedGoogle Scholar
  24. 24.
    Freund V, Frossard N (2004) Expression of nerve growth factor in the airways and its possible role in asthma. Prog Brain Res 146: 335–346PubMedCrossRefGoogle Scholar
  25. 25.
    Fukuoka M, Sakurai K, Ohta T, et al. (2001) Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes. Skin Pharmacol Appl Skin Physiol 14: 226–233PubMedGoogle Scholar
  26. 26.
    Gigante A, Bevilacqua C, Pagnotta A, et al. (2003) Expression of NGF, TrkA and p75 in human cartilage. Eur J Histochem 47: 339–344PubMedGoogle Scholar
  27. 27.
    Giovengo SL, Russell IJ, Larson AA (1999) Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 26: 1564–1569PubMedGoogle Scholar
  28. 28.
    Hamada A, Watanabe N, Ohtomo H, Matsuda H (1996) Nerve growth factor enhances survival and cytotoxic activity of human eosinophils. Br J Haematol 93: 299–302PubMedCrossRefGoogle Scholar
  29. 29.
    Hellweg R, Baethge C, Hartung HD, et al. (1996) NGF level in the rat sciatic nerve is decreased after long-term consumption of ethanol. Neuroreport 7: 777–780PubMedCrossRefGoogle Scholar
  30. 30.
    Iannone F, De Bari C, Dell’Accio F, et al. (2002) Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. Rheumatology (Oxford) 41: 1413–1418CrossRefGoogle Scholar
  31. 31.
    Jockers-Scherübl MC, Zubraegel D, Baer T, et al. (2007) Nerve growth factor serum concentrations rise after successful cognitive-behavioural therapy of generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 31: 200–204PubMedCrossRefGoogle Scholar
  32. 32.
    Kakinoki B, Sekimoto S, Yuki S, et al. (2006) Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. Diabetes 55: 616–621PubMedCrossRefGoogle Scholar
  33. 33.
    Kawamoto K, Matsuda H (2004) Nerve growth factor and wound healing. Prog Brain Res 146: 369–384PubMedCrossRefGoogle Scholar
  34. 34.
    Kim SK, Son CG, Yun CH, Han SH (2010) Hericiumerinaceum induces maturation of dendritic cells derived from human peripheral blood monocytes. Phytother Res 24: 14–19PubMedCrossRefGoogle Scholar
  35. 35.
    Kimura S, Yoshino A, Katayama Y, et al. (2002) Growth control of C6 glioma in vivo by nerve growth factor. J Neurooncol 59: 199–205PubMedCrossRefGoogle Scholar
  36. 36.
    Klinger MB, Vizzard MA (2008) Role of p75NTR in female rat urinary bladder with cyclophosphamide-induced cystitis. Am J Physiol Renal Physiol 295: F1778–F89PubMedCrossRefGoogle Scholar
  37. 37.
    Koliatsos VE (1996) Biological therapies for Alzheimer’s disease: focus on trophic factors. Crit Rev Neurobiol 10: 205–238PubMedGoogle Scholar
  38. 38.
    Kolotushkina EV, Moldavan MG, Voronin KY, Skibo GG (2003) The influence of Hericium erinaceus extract on myelination process in vitro. Fiziol Zh 1: 38–34Google Scholar
  39. 39.
    Knüpfer H, Arendt T (2001) NGF increases cell survival rates under serum deprived conditions. Anticancer Res 21: 2797–2802PubMedGoogle Scholar
  40. 40.
    Lambiase A, Aloe L (1996) Nerve growth factor delays retinal degeneration in C3H mice. Arch Clin Exp Ophtalml 234(Suppl 1): S96–S100CrossRefGoogle Scholar
  41. 41.
    Lambiase A, Coassin M, Tirassa P, et al. (2009) Nerve growth factor eye drops improve visual acuity and electrofunctional activity in age-related macular degeneration: a case report. Ann Ist Super Sanita 45: 439–442PubMedGoogle Scholar
  42. 42.
    Lara HE, Dissen GA, Leyton V, et al. (2000) An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology 141: 1059–1072PubMedCrossRefGoogle Scholar
  43. 43.
    Levi-Montalcini R (2004) The nerve growth factor and the neuroscience chess board. Prog Brain Res 146: 525–527PubMedGoogle Scholar
  44. 44.
    Lee JS, Hong EK (2010) Hericium erinaceus enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells. Cancer Lett 297: 144–154PubMedCrossRefGoogle Scholar
  45. 45.
    Lee JS, Min KM, Cho JY, Hong EK (2009) Study of macrophage activation and structural characteristics of purified polysaccharides from the fruiting body of Hericium erinaceus. J Microbiol Biotechnol 19: 951–959PubMedCrossRefGoogle Scholar
  46. 46.
    Lee EW, Shizuki K, Hosokawa S, et al. (2000) Two novel diterpenoids, erinacines H and I from the mycelia of Hericiummerinaceus. Biosci Biotechnol Biochem 64: 2402–2405PubMedCrossRefGoogle Scholar
  47. 47.
    Li Y, Zhang G, Ng TB, Wang H (2010) A novel lectin with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from dried fruiting bodies of the monkey head mushroom Hericiumerinaceum. J Biomed Biotechnol 2010: 716515PubMedGoogle Scholar
  48. 48.
    Lowe EM, Anand P, Terenghi G, et al. (1997) Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 572: 572–577Google Scholar
  49. 49.
    Manni L, Nikolova V, Vyagova D, et al. (2005) Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol 102: 169–171PubMedCrossRefGoogle Scholar
  50. 50.
    Mori K, Inatomi S, Ouchi K, et al. (2009) Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double blind placebo-controlled clinical trial. Phytother Res 23: 367–372PubMedCrossRefGoogle Scholar
  51. 51.
    Mori K, Obara Y, Hirota M, et al. (2008) Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull 31: 1727–1732PubMedCrossRefGoogle Scholar
  52. 52.
    Nagai K, Chiba A, Nishino T, et al. (2006) Dilinoleoyl-phosphatidylethanolamine from Hericium erinaceum protects against ER stress-dependent Neuro2a cell death via protein kinase C pathway. J Nutr Biochem 17: 525–530PubMedCrossRefGoogle Scholar
  53. 53.
    Nagano M, Shimizu K, Kondo R, et al. (2010) Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res 31: 231–237PubMedCrossRefGoogle Scholar
  54. 54.
    Patterson JC, Childs GV (1994) Nerve growth factor in the anterior pituitary: regulation of secretion. Endocrinology 135: 1697–1704PubMedCrossRefGoogle Scholar
  55. 55.
    Pisano C, Pratesi G, Laccabue D, et al. (2003) Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 9: 5756–5767PubMedGoogle Scholar
  56. 56.
    Pradat PF (2003) Treatment of peripheral neuropathies with neutrotrophic factors: animal models and clinical trials. Rev Neurol (Paris) 159: 147–161Google Scholar
  57. 57.
    Saito T, Aoki F, Hirai H, et al. (1998) Erinacine E as a kappa opioid receptor agonist and its new analogs from a basidiomycete, Hericiumramosum. J Antibiot (Tokyo) 51: 983–990Google Scholar
  58. 58.
    Samina Riaz S, Tomlinson DR (2000) Pharmacological modulation of nerve growth factor synthesis: a mechanistic comparison of vitamin D receptor and beta(2)-adrenoceptor agonists. Brain Res Mol Brain Res 85: 179–188PubMedCrossRefGoogle Scholar
  59. 59.
    Santambrogio L, Benedetti M, Chao MV, et al. (1994) Nerve growth factor production by lymphocytes. J Immunol 153: 4488–4495PubMedGoogle Scholar
  60. 60.
    Sarchielli P, Mancini ML, Floridi A, et al. (2007) Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 8: 737–745PubMedCrossRefGoogle Scholar
  61. 61.
    Schnegelsberg B, Sun TT, Cain G, et al. (2010) Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity and changes in urinary bladder function. Am J Physiol Regul Integr Comp Physiol 298: R534–R547PubMedGoogle Scholar
  62. 62.
    Scott SA, Mufson EJ, Weingartner JA, et al. (1995) Nerve growth factor in Alzheimer’s disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 15: 6213–6221PubMedGoogle Scholar
  63. 63.
    Son CG, Shin JW, Cho JH, et al. (2006) Induction of murine interleukin-1 beta expression by water-soluble components from Hericiumerinaceum. Acta Pharmacol Sin 27: 1058–1064PubMedCrossRefGoogle Scholar
  64. 64.
    Stadler M, Mayer A, Anke H, Sterner O (1994) Fatty acids and other compounds with nematicidal activity from cultures of Basidiomycetes. Planta Med 60: 128–132PubMedCrossRefGoogle Scholar
  65. 65.
    Sun W, Sun C, Lin H, et al. (2009) The effect of collagen-binding NGF-beta on the promotion of sciatic nerve regeneration in a rat sciatic nerve crush injury model. Biomaterials 30: 4649–4656PubMedCrossRefGoogle Scholar
  66. 66.
    Torcia M, De Chiara G, Nencioni L, et al. (2001) Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release. J Biol Chem 42: 39027–39036CrossRefGoogle Scholar
  67. 67.
    Tuszynski M, Blesch A (2004) Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer’s disease. Prog Brain Res 146: 441–449PubMedGoogle Scholar
  68. 68.
    Ueda K, Kodani S, Kubo M, et al. (2009) Endoplasmic reticulum (ER) stress-suppressive compounds from scrap cultivation beds of the mushroom Hericiumerinaceum. Biosci Biotechnol Biochem 73: 1908–1910PubMedCrossRefGoogle Scholar
  69. 69.
    Villoslada P, Genain CP (2004) Role of nerve growth factor and other trophic factors in brain inflammation. Prog Brain Res 146: 403–414PubMedCrossRefGoogle Scholar
  70. 70.
    Villoslada P, Hauser SL, Bartke I, et al. (2000) Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 191: 1799–1806PubMedCrossRefGoogle Scholar
  71. 71.
    Wang JC, Hu SH, Su CH, Lee TM (2001) Antitumor and immunoenhancing activities of polysaccharide from culture broth of Hericium spp. Kaohsiung J Med Sci 17: 461–467PubMedGoogle Scholar
  72. 72.
    Xu CP, Liu WW, Liu FX, et al. (1985) A double blind study of effectiveness of Hericium erinaceus pers therapy on chronic atrophic gastritis. A preliminary report. Chin Med J (Engl) 98: 455–456Google Scholar
  73. 73.
    Xu H, Wu PR, Shen ZY, Chen XD (2010) Chemical analysis of Hericium erinaceum polysaccharides and effect of the polysaccharides on derma antioxidant enzymes, MMP-1 and TIMP-1 activities. Int J Biol Macromol 47: 33–36PubMedCrossRefGoogle Scholar
  74. 74.
    Yim MH, Shin JW, Son JY, et al. (2007) Soluble components of Hericium erinaceum induce NK cell activation via production of interleukin-12 in mice splenocytes. Acta Pharmacol Sin 28: 901–907PubMedCrossRefGoogle Scholar
  75. 75.
    Yoshimura N, Bennett NE, Hayashi Y, et al. (2006) Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci 26: 10847–10855PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag 2011

Authors and Affiliations

  1. 1.Médecine Information ÉducationCormontreuilFrance

Personalised recommendations